With a thyroid‑stimulating hormone (TSH) of 0.06 mIU/L and a free thyroxine (free T4) of 1.23 ng/dL, what should be the next steps in management?

Management of Low TSH (0.06 mIU/L) with Normal FT4 (1.23 ng/dL)

Repeat TSH measurement along with free T3 within 4 weeks to confirm subclinical hyperthyroidism, then pursue etiology with radioactive iodine uptake and scan if confirmed. 1

Immediate Next Steps

Your patient has a TSH of 0.06 mIU/L (below 0.1 mIU/L) with normal free T4, which represents subclinical hyperthyroidism. This requires a structured approach:

1. Confirm the Diagnosis (Within 4 Weeks)

• Repeat TSH measurement 1
• Add free T3 or total T3 to rule out T3 thyrotoxicosis 1
• If the patient has cardiac symptoms, atrial fibrillation, other arrhythmias, or signs of hyperthyroidism, perform these tests within a shorter interval 1

Critical caveat: T3 thyrotoxicosis is rare (only 0.5% of new diagnoses in one large study), and nearly all cases of newly diagnosed hyperthyroidism had TSH <0.01 mIU/L 2. Your patient's TSH of 0.06 sits just above this threshold, making isolated T3 toxicosis less likely but still worth checking.

2. Determine if Endogenous vs. Exogenous

Ask specifically about:

• Current levothyroxine use (dose and indication)
• History of thyroid cancer or thyroid nodules
• Recent iodine exposure (contrast studies, supplements)

If on levothyroxine:

• Review the indication immediately 1
• If prescribed for simple hypothyroidism (not cancer or nodules), decrease the levothyroxine dose to allow TSH to rise toward the reference range 1
• If prescribed for thyroid cancer or nodules requiring TSH suppression, consult with the treating endocrinologist to review target TSH 1

If NOT on levothyroxine (endogenous cause):

3. Establish Etiology with Imaging

• Obtain radioactive iodine uptake and scan to distinguish between: 1
  • Graves disease (increased uptake, diffuse)
  • Toxic nodular goiter (increased uptake, focal)
  • Destructive thyroiditis (low uptake) - which resolves spontaneously

4. Assess for High-Risk Features Requiring Treatment

Evaluate for cardiac complications:

• Atrial fibrillation or other arrhythmias
• Signs of cardiac disease
• Age >65 years (increased cardiovascular mortality risk) 1

Treatment considerations:

• TSH <0.1 mIU/L with Graves or nodular disease: Treatment should be considered, particularly in elderly patients or those with cardiac disease 1
• Destructive thyroiditis: Usually requires only symptomatic therapy (β-blockers); resolves spontaneously 1
• The guideline found insufficient evidence for routine treatment when TSH is mildly decreased (0.1-0.45 mIU/L), but your patient falls below this threshold at 0.06 mIU/L 1

5. Monitoring Strategy if Not Treating Immediately

If confirmed subclinical hyperthyroidism but no immediate treatment indicated:

• Retest at 3- to 12-month intervals until TSH normalizes or condition is stable 1
• Watch for development of overt hyperthyroidism, especially if nodular thyroid disease present and patient exposed to excess iodine 1

Key Pitfalls to Avoid

• Don't assume overtreatment without checking medication history - endogenous causes require different management
• Don't delay cardiac evaluation in symptomatic or elderly patients - cardiovascular mortality may be increased even with subclinical disease 1
• Don't order free T3 reflexively - it has limited utility except when TSH is profoundly suppressed (<0.01 mIU/L) 2
• Don't treat destructive thyroiditis with antithyroid drugs - it resolves spontaneously and only needs symptomatic management 1